• Return to HOME


  • Home
  • Services
    • Clinical & Medical Consulting
    • Business Development
    • Pharmaceutical
    • Regulatory Affairs
    • Legal Consulting
  • Our Team
    • Michael Epstein, MD, FACG, AGAF
  • News
  • Blog
  • Contact


IBgard safe, well-tolerated in IBS patients

October 21, 2016
by Epstein Associates
Comments are off

ibgard

Six-month data from a real-world surveillance study shows over-the-counter IBgard is safe and well-tolerated in patients with irritable bowel syndrome, according to a press release from the manufacturer.

IBgard (IM HealthScience) capsules use site specific delivery technology to release highly purified peppermint oil to the small intestine to help normalize digestion, nutrient absorption and intestinal transit time.

Previous randomized controlled trial data have shown rapid IBS symptom relief, high satisfaction and improved quality of life among patients who used IBgard. In the current IBS Safety Update at 6 months (IBSSU-6) study, researchers evaluated data on adverse events and serious adverse events reported by more than 163,000 patients who used the product from October 5, 2015 through May 31, 2016.

“Real-world research is a vital component to clinical trials and helps with defining management options for patients,” Michael S. Epstein, MD, FACG, AGAF, a gastroenterologist and chief medical advisor for IM HealthScience, said in the press release. “The findings from IBSSU-6 reaffirm the safety and tolerability profile of IBgard in real-world settings and show the use of IBgard is consistent with the adverse events reported in our landmark clinical trial, IBSREST.”

In the IBSSU-6 study, no serious adverse events occurred, and non-serious adverse events occurred in 0.05% of patients. These included dyspepsia, nausea, abdominal pain and diarrhea, which occur in comparable rates and patterns in the general IBS population, according to the press release.

“Heartburn and anal burning are common side effects associated with older peppermint oil products,” Epstein said in the press release. “However, in IBSSU-6, there were no reports of anal burning and reports of heartburn were remarkably low, no different than what physicians see as existing co-morbid conditions in the patient population suffering from IBS.”

From Drug Store News: Study reaffirms safety and tolerability profile of leading IBS medical food

IM HealthScience on Monday announced favorable results from its Irritable Bowel Syndrome Safety Update at 6 Months (IBSSU-6), a real-world surveillance study reporting on the safety and tolerability profile of IBgard among an estimated 163,165 patients who used the product. – Drug Store News, August 29, 2016

Read the entire article online

About the Author
Social Share
  • google-share

Key Services

  • Clinical & Medical Consulting
  • Business Development
  • Pharmaceutical
  • Regulatory Affairs
  • Legal Consulting

News & Announcements

Achieving successful bowel preparation with evening/morning split-dosing regimens of NER1006 versus trisulfate: post hoc analysis of a Phase 3 trial
Jul 25, 2017
Novel 1L Polyethylene Glycol (PEG)-Based Bowel Preparation NER1006 Achieves High Quality Bowel Cleansing with a Lower Volume than Standard 2L PEG + Ascorbate and Under 3L Total Fluid Volume Intake
Jul 25, 2017
Bowel preparation quality of NER1006 versus oral trisulfate solution as assessed by colonoscopists at site: a post hoc analysis from a randomized controlled trial
Jul 25, 2017

410-224-4887 x453

Epstein Associates, LLC
621 Ridgely Avenue, Suite 204
Annapolis, MD 21401

  • Home
  • Services
  • Our Team
  • News
  • Blog
  • Contact

© Copyright 2015, Epstein Associates, LLC
Website Design by Calvert Design Group, Inc.